Can two antibodies free HIV patients from daily pills? early trial launches

NCT ID NCT06987318

Not yet recruiting Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests whether two lab-made antibodies can help people with HIV control the virus after stopping their regular antiretroviral therapy. The 40 participants all started HIV treatment very early after infection. Researchers will monitor safety and see if the antibodies keep virus levels low during a temporary break from daily medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Two human antibodies (VRC07-523LS and PGT121.414.LS) given by IV infusion
What this could lead to: If successful, this could point toward a way for some people with HIV to control the virus without daily medication, potentially reducing lifelong drug dependence.
What could go wrong: This is a very early Phase 1 trial with only 40 participants, so results may not apply broadly. The antibodies may not suppress the virus for long, and there are risks of side effects or the virus becoming resistant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

Alabama CRS

Birmingham, Alabama, 35222, United States
Barranco CRS

Lima, 15063, Peru
Chapel Hill CRS

Chapel Hill, North Carolina, 27599-7215, United States
Houston Advancing Research Team CRS

Houston, Texas, 77030, United States
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS

Rio de Janeiro, 21040-900, Brazil
Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS

Porto Alegre, Rio Grande do Sul, 91350-180, Brazil
Massachusetts General Hospital CRS (MGH CRS)

Boston, Massachusetts, 02114, United States
Northwestern University CRS

Chicago, Illinois, 60611, United States
Ohio State University CRS

Columbus, Ohio, 43210, United States
Penn Therapeutics CRS

Philadelphia, Pennsylvania, 19104, United States
The Ponce de Leon Center CRS

Atlanta, Georgia, 30308-2012, United States
UCSD Antiviral Research Center CRS

San Diego, California, 92103, United States
University of Colorado Hospital CRS

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.